Abstract
Patients with inflammatory bowel disease (IBD)frequently suffer from thromboembolic events.Anti-cardiolipin (aCL) antibodies have been shown to beassociated with thrombosis. Recently, the antibodies against the anti-cardiolipin cofactorβ2-glycoprotein I(aβ2GPI) have been found with higherspecificity for thrombosis. The presence of theseantibodies was assessed in 128 patients with IBD [83 with ulcerative colitis (UC) and 45 withCrohn's disease (CD)] and 100 healthy controls (blooddonors). Patients with UC and CD had a significantlyhigher prevalence of aCL (18.1% and 15.6%, respectively) than healthy controls (HC) (3%). Eleven IBDpatients (8.6%) but no HC had aβ2GPI.None of the IBD patients with a history of thrombosishad aCL and only one of them (a UC patient with deepvein thrombosis of the right leg) had a high titer of IgGaβ2GPI. In conclusion, these data showthat both aCL and aβ2GPI aresignificantly associated with IBD but further studiesare needed to determine the significance of our findings.
Similar content being viewed by others
REFERENCES
Talbot RW, Heppell J, Dozois RR, Beart R Jr: Vascular complications of inflammatory bowel disease. Mayo Clin Proc 61:140 - 145, 1986
Webbe rley MJ, Hart MT, Melikian V: Thromboembolism in inammatory bowel disease: Role of platelets. Gut 34:247- 251, 1993
Collins CE, Rampton DS: Review article: platelets in inflammatory bowel disease—pathogenetic role and therapeutic implications. Aliment Pharmacol The r 11:237- 247, 1997
Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F: Thrombosis in in¯ ammatory bowel disease: Clinical se tting, procoagulant profi le and factor V Leiden. Q J Med 90:183- 188, 1997
Graef V, Bagge nstoss AH, Sauer WG, Spittell JAJ: Venous thrombosis occurring in non-specifi c ulcerative colitis. Arch Intern Med 117:377- 382, 1965
Wake fi eld AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Raule s PM, Lewis AAM, Pounder RE: Pathogenesis of Crohn's disease. Lancet 2:1057- 1062, 1989
Gaffney PR, Doyle CT, Gaffney A, Hogan J, Haye s DP, Annis P: Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroente rol 90:220 - 223, 1995
Thompson NP, Wakefi eld AJ, Pounder RE: Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 108:1011- 1015, 1995
Lam A, Borda IT, Inwood MJ, Thomson S: Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology 68:245- 251, 1975
Lake AM, Stauffer JQ, Stuart MJ: Hemostatic alterations in inflammatory bowel disease. Am J Dig Dis 23:897- 902, 1978
Souto JC, Martinez E, Roca M, Mateo J, Puzol J, Gonzalez D, Fontcuberta J: Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 40:1883- 1889, 1995
Chamouard P, Grunebaum L, Wiesel ML, Frey PL, Wittershein C, Sapin R, Baumann R, Cazenave JP: Prothrombin fragment 1 1 2 and thrombin- antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroente rol Hepatol 7:1183- 1188, 1995
Aadland E, Odegaard OR, Roseth A, Try K: Fre e protein S defi ciency in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 27:957- 960, 1992
Stevens TR, Jame s JP, Simmonds NJ, McCarthy OA, Laurenson IF, Maddison PJ, Rampton DS: Circulating von Willebrand factor in inflammatory bowel disease. Gut 33:502- 506, 1992
Stadnicki A, Gonciarz M, Niewiarowski TJ, Hartleb J, Rudnicki M, Merre ll NB, De la Cadena RA, Colman RW: Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis. Dig Dis Sci 42:2356 - 2366, 1997
Chamouard P, Grunebaum L, Wiesel ML, Freyssinet JM, Duclos B, Cazenave JP, Baumann R: Prevalence and signifi cance of anticardiolipin antibodies in Crohn's disease. Dig Dis Sci 39:1501- 1504, 1994
Lonjon I, Beaugerie L, Deschamps A, Barthet C, Carbonnel F, Ngo Y, Coshes J, Abuaf N, Gendre JP: Prevalence and role of anticardiolipin antibodies in Crohn disease. Gastroente rol Clin Biol 20:633- 637, 1996
Dalekos GN, Manoussakis MN, Goussia AC, Tsianos EV, Moutsopoulos HM: Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodie s in patients with ulcerative colitis. Gut 34:658 - 864, 1993
Ginsburg KS, Liang MH, Newcome r L, Goldhaber SZ, Schur PH, Henneke ns CH, Stampfer MJ: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117:997- 1002, 1992
Bick RL: Antiphospholipid thrombosis syndrome s: Etiology, pathophysiology, diagnosis and management. Int J Hematol 65:193- 213, 1997
Galli M, Comfurius P, Maasse n C, Hanker HC, de Be ets MH, van Brede-Vriesman PJ, Barbui T, Zwad RF, Beve rs EM: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lance t 335:1544 - 1547, 1990
Hanly JG, Hong C, Jame s H, Mansour M, Jone s JV: Requirement of beta 2 glycoprote in I as cofactor in the binding for IgM and IgA anticardiolipin antibodies. J Rheumatol 22:1091- 1096, 1995
Ke il LB, Galazka M, e l-Kadi HS, Erickson E Jr, DeBari VA: Binding of beta 2 glycoprote in I to activate d polystyrene and its recognition by human IgG autoantibodies. Biotechnol Appl Biochem 22:305- 313, 1995
Martinuzzo ME, Forastie ro RR, Carre ras LO: Anti beta 2 glycoprote in I antibodie s: detection and association with thrombosis. Br J Haematol 89:397- 402, 1995
Forastiero RR, Martinuzzo ME, Kordich LC, Carreras LO: Reactivity to beta 2 glycoprote in I cle arly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 75:717- 720, 1996
Sanmarco M, Soler C, Christides C, Raoult D, We iller PJ, Gerolami V, Be rnard D: Prevalence and clinical signifi cance of IgG isotype anti-beta 2-glycoprotein I antibodies in antiphospholipid syndrome: A comparative study with anticardiolipin antibodies. J Lab Clin Med 129:499 - 506, 1997
Lennard-Jones JE: Classifi cation of inflammatory bowel disease. Scand J Gastroente rol Suppl 24:2- 6, 1989
Best WR, Be cketl JM, Singleton JW, Kern F Jr: De velopment of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroente rology 70:439 - 444, 1976
Truelove SC, Witts LJ: Cortisone in ulcerative colitis. Br Med J 2:1041- 1044, 1955
Schousboe I: Be ta 2-glycoprotein I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 66:1086 - 1091, 1985
Brighton TA, Hogg PJ, Dai YP, Murray BH, Chong BH, Chesterman CN: Be ta 2-glycoprotein I in thrombosis: Evidence for a role as a natural anticoagulant. Br J Haematol 93:185- 194, 1996
Del Papa N, Guidali L, Spatola L, Bonara P, Borghi MO, Tincani A, Balestrieri G, Meroni PL: Relationship between anti-phospholipid and anti-endothelial cell antibodies III: Beta 2 glycoprotein I mediate s the antibody binding to endothelial membrane s and induces the expression of adhe sion molecule s. Clin Exp Rheumatol 13:179 - 185, 1995
Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein RL: Activation of cultured vascular endothelial ce lls by antiphospholipid antibodies. J Clin Invest 96:2211- 2219, 1995
Del Papa N, Raschi E, Catelli L, Khamashta MA, Ishikawa K, Tincani A, Balestrieri G, Meroni PL: Endothelial cells as a target for antiphospholipid antibodies: Role of anti-beta 2 glycoprotein I antibodies. Am J Reprod Immunol 38:212- 217, 1997
Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Sche r J, Harpel PC: Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic me chanism. N Engl J Med 337:154 - 160, 1997
Hudson M, Chitolie A, Hutton RA, Smith MS, Pounder RE, Wake fi eld AJ: Thrombotic vascular risk factors in inflammatory bowel disease. Gut 38:733- 737, 1996
Vecchi M, Cattaneo M, de Franchis R, Mannucci PM: Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res 21:165- 170, 1991
Chiarantini E, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, Prisco P, Tonelli F, Abbate R: Hemostatic abnormalities in inflammatory bowel disease. Thromb Res 82:137- 146, 1991
Souto JC, Borrell M, Fontcuberta J, Roca M: Antiphospholipid antibodies in inflammatory bowel disease. Dig Dis Sci 40:1524 - 1525, 1995
El-Kadi HS, Ke il LB, DeBari VA: Analytical and clinical relationships between human IgG autoantibodies to beta 2 glycoprotein I and anticardiolipin antibodies. J Rheumatol 22:2233- 2237, 1995
McNally T, Mackie IJ, Machin SJ, Isenberg DA: Incre ased leve ls of beta 2 glycoprote in-I antigen and beta 2 glycoprote in-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 34:1031- 1036, 1995
Roubey RA, Maldonado MA, Byrd SN: Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprote in I and a conventional anticardiolipin immunoassay. Arthritis Rheum 39:1606 - 1607, 1996
Teixido M, Font J, Reve rte r JC, Cervera R, Tassies D, Ingelmo M, Escolar G, Ordinas A: Anti-beta 2-glycoprotein I antibodies: a useful marke r for the antiphospholipid syndrome. Br J Rheumatol 36:113- 116, 1997
Rights and permissions
About this article
Cite this article
Koutroubakis, I.E., Petinaki, E., Anagnostopoulou, E. et al. Anti-cardiolipin and Anti-β2-glycoprotein I Antibodies in Patients with Inflammatory Bowel Disease. Dig Dis Sci 43, 2507–2512 (1998). https://doi.org/10.1023/A:1026602803622
Issue Date:
DOI: https://doi.org/10.1023/A:1026602803622